| Donald E Hauser, MD | |
|
5959 West Loop S, Suite 600, Bellaire, TX 77401-2421 | |
| (713) 669-0303 | |
| (713) 669-0704 |
| Full Name | Donald E Hauser |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 41 Years |
| Location | 5959 West Loop S, Bellaire, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316990674 | NPI | - | NPPES |
| 807842 | Other | TX | BLUE CROSS BLUE SHIELD |
| 0022796 | Other | TX | VALUE OPTIONS |
| 260008967 | Other | TX | RAILROAD MEDICARE |
| P08078423 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | G5154 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hauser Clinic And Associates Inc | 4688698426 | 5 |
News Archive
The New York Times reports on this push, which is one of several ways some are discussing to get around the current technology problems plaguing the Obama administration's enrollment effort. Also in the news, The Wall Street Journal reports that some of these difficulties are trickling down from the federal online insurance marketplace to certain state exchanges.
The National Institutes of Health, under the National Library of Medicine's program on data science research, has awarded $1.55 million to an interdisciplinary team lead by Luis Rocha, a professor of informatics and the director of the NSF-NRT complex networks and systems program at the Indiana University School of Informatics, Computing and Engineering.
The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.
Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
› Verified 9 days ago
| Entity Name | Hauser Clinic And Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245397165 PECOS PAC ID: 4688698426 Enrollment ID: O20060119000909 |
News Archive
The New York Times reports on this push, which is one of several ways some are discussing to get around the current technology problems plaguing the Obama administration's enrollment effort. Also in the news, The Wall Street Journal reports that some of these difficulties are trickling down from the federal online insurance marketplace to certain state exchanges.
The National Institutes of Health, under the National Library of Medicine's program on data science research, has awarded $1.55 million to an interdisciplinary team lead by Luis Rocha, a professor of informatics and the director of the NSF-NRT complex networks and systems program at the Indiana University School of Informatics, Computing and Engineering.
The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.
Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
› Verified 9 days ago
| Entity Name | Methodist Physician Practices Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922252717 PECOS PAC ID: 8022171974 Enrollment ID: O20090121000165 |
News Archive
The New York Times reports on this push, which is one of several ways some are discussing to get around the current technology problems plaguing the Obama administration's enrollment effort. Also in the news, The Wall Street Journal reports that some of these difficulties are trickling down from the federal online insurance marketplace to certain state exchanges.
The National Institutes of Health, under the National Library of Medicine's program on data science research, has awarded $1.55 million to an interdisciplinary team lead by Luis Rocha, a professor of informatics and the director of the NSF-NRT complex networks and systems program at the Indiana University School of Informatics, Computing and Engineering.
The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.
Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
› Verified 9 days ago
| Entity Name | First Step To Recovery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518619519 PECOS PAC ID: 5890172860 Enrollment ID: O20220512000626 |
News Archive
The New York Times reports on this push, which is one of several ways some are discussing to get around the current technology problems plaguing the Obama administration's enrollment effort. Also in the news, The Wall Street Journal reports that some of these difficulties are trickling down from the federal online insurance marketplace to certain state exchanges.
The National Institutes of Health, under the National Library of Medicine's program on data science research, has awarded $1.55 million to an interdisciplinary team lead by Luis Rocha, a professor of informatics and the director of the NSF-NRT complex networks and systems program at the Indiana University School of Informatics, Computing and Engineering.
The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.
Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald E Hauser, MD 7777 Southwest Fwy, Suite 900, Houston, TX 77074-1802 Ph: (713) 981-9971 | Donald E Hauser, MD 5959 West Loop S, Suite 600, Bellaire, TX 77401-2421 Ph: (713) 669-0303 |
News Archive
The New York Times reports on this push, which is one of several ways some are discussing to get around the current technology problems plaguing the Obama administration's enrollment effort. Also in the news, The Wall Street Journal reports that some of these difficulties are trickling down from the federal online insurance marketplace to certain state exchanges.
The National Institutes of Health, under the National Library of Medicine's program on data science research, has awarded $1.55 million to an interdisciplinary team lead by Luis Rocha, a professor of informatics and the director of the NSF-NRT complex networks and systems program at the Indiana University School of Informatics, Computing and Engineering.
The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.
Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
› Verified 9 days ago
Dr. Kenneth Arfa, M. D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6300 West Loop S, Suite 390, Bellaire, TX 77401 Phone: 713-723-5774 | |
Dr. Mark S Moeller, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6300 West Loop S, Suite 680, Bellaire, TX 77401 Phone: 713-661-4670 Fax: 713-661-4672 | |
Dr. Linda Jean Cordell, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 4545 Bissonnet St, Suite 120, Bellaire, TX 77401 Phone: 713-669-0373 Fax: 713-669-0217 | |
James L. Claghorn, M.D Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6750 West Loop S Ste 1050, Bellaire, TX 77401 Phone: 713-665-6446 Fax: 713-665-6483 | |
Dr. Mary Ellen Vanderlick, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6700 West Loop S Ste 400, Bellaire, TX 77401 Phone: 713-704-6731 Fax: 713-704-1796 | |
Mrs. Hayley Epstein Maislos, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5959 West Loop South Suite 600, Bellaire, TX 77401 Phone: 713-669-0303 Fax: 713-669-0704 | |
Dr. Kathleen Ru-drung Yen, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6300 West Loop S Ste 645, Bellaire, TX 77401 Phone: 832-358-3489 |